Viking Therapeutics (VKTX) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $26.1 million.
- Viking Therapeutics' Total Current Liabilities rose 148.72% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 148.72%. This contributed to the annual value of $27.4 million for FY2024, which is 4326.1% up from last year.
- Per Viking Therapeutics' latest filing, its Total Current Liabilities stood at $26.1 million for Q3 2025, which was up 148.72% from $32.0 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Total Current Liabilities registered a high of $32.8 million during Q1 2024, and its lowest value of $8.8 million during Q4 2021.
- For the 5-year period, Viking Therapeutics' Total Current Liabilities averaged around $18.9 million, with its median value being $15.6 million (2023).
- Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 15002.28% in 2022, then crashed by 4027.89% in 2025.
- Over the past 5 years, Viking Therapeutics' Total Current Liabilities (Quarter) stood at $8.8 million in 2021, then skyrocketed by 150.02% to $21.9 million in 2022, then fell by 12.81% to $19.1 million in 2023, then soared by 43.26% to $27.4 million in 2024, then decreased by 4.91% to $26.1 million in 2025.
- Its Total Current Liabilities was $26.1 million in Q3 2025, compared to $32.0 million in Q2 2025 and $19.6 million in Q1 2025.